Legend Biotech Corp
9LB
Company Profile
Business description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Contact
2101 Cottontail Lane
SomersetNJ08873
USAT: +1 737 317-5050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,609
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 26.20 | 0.32% |
| CAC 40 | 8,094.20 | 77.27 | -0.95% |
| DAX 40 | 22,999.15 | 288.91 | -1.24% |
| Dow JONES (US) | 41,953.32 | 11.31 | -0.03% |
| FTSE 100 | 8,701.99 | 4.67 | -0.05% |
| HKSE | 23,733.02 | 486.93 | -2.01% |
| NASDAQ | 17,691.63 | 59.16 | -0.33% |
| Nikkei 225 | 37,920.79 | 168.91 | 0.45% |
| NZX 50 Index | 12,113.54 | 58.82 | 0.49% |
| S&P 500 | 5,662.89 | 12.40 | -0.22% |
| S&P/ASX 200 | 7,948.00 | 29.10 | 0.37% |
| SSE Composite Index | 3,376.96 | 31.99 | -0.94% |